Amazon's GLP-1 Program Limits Impact Hims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy HIMS?
Source: stocktwits
- Amazon's GLP-1 Program Limits: Citi highlighted that Amazon's $29 telehealth option is restricted to prescription renewals, not new prescriptions, which may reduce the competitive threat to Hims' subscription model, impacting its market position.
- Hims Stock Volatility: Hims & Hers Health, Inc. (HIMS) saw its shares drop over 4% to $29.76 in extended trading on Tuesday, although they rebounded by more than 1% after hours, indicating mixed market sentiment regarding its future prospects.
- Hims Expanding New Areas: Hims is diversifying into hormone health, with the FDA recently encouraging testosterone therapy exploration for men with low libido, potentially opening new market opportunities while also advancing FDA-approved GLP-1 therapies.
- Positive Market Sentiment: Despite competition from Amazon, Hims has been viewed as “extremely bullish” on Stocktwits, with message volumes surging 384% over the past week, reflecting investor confidence in its innovative capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 31.010
Low
16.50
Averages
32.95
High
60.00
Current: 31.010
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon's GLP-1 Program Limits Impact Hims
- Amazon's GLP-1 Program Limits: Citi highlighted that Amazon's $29 telehealth option is restricted to prescription renewals, not new prescriptions, which may reduce the competitive threat to Hims' subscription model, impacting its market position.
- Hims Stock Volatility: Hims & Hers Health, Inc. (HIMS) saw its shares drop over 4% to $29.76 in extended trading on Tuesday, although they rebounded by more than 1% after hours, indicating mixed market sentiment regarding its future prospects.
- Hims Expanding New Areas: Hims is diversifying into hormone health, with the FDA recently encouraging testosterone therapy exploration for men with low libido, potentially opening new market opportunities while also advancing FDA-approved GLP-1 therapies.
- Positive Market Sentiment: Despite competition from Amazon, Hims has been viewed as “extremely bullish” on Stocktwits, with message volumes surging 384% over the past week, reflecting investor confidence in its innovative capabilities.
See More
Hims & Hers Stock Declines Amid Amazon Competition
- Stock Fluctuation: Hims & Hers Health closed at $29.76, down 4.03%, primarily impacted by Amazon's launch of a competing GLP-1 weight-loss program, although it gained 39.33% over the past week.
- Surge in Trading Volume: Trading volume reached 56.7 million shares, about 50% above the three-month average of 37.8 million shares, indicating increased market interest in the stock.
- Intensified Market Competition: Amazon's same-day delivery service poses a threat to Hims & Hers' core business, especially following the resolution of a legal dispute with Novo Nordisk over weight-loss drugs, which has dampened market sentiment.
- Investor Watch: Investors will closely monitor the potential impact of Amazon's new offering on Hims & Hers' revenue and subscriber numbers, particularly as the company is set to announce its Q1 results on May 11.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 99.53 points to 26,689.87, indicating positive market sentiment that may attract more investor interest.
- Active Stocks: Local Bounti Corporation (LOCL) increased by $1.0305 in pre-market trading, with a volume of 35,128,203 shares, indicating a significant uptick in the company's market activity.
- ETF Performance: Direxion Daily TSLA Bull 2X ETF (TSLL) rose by $0.2 to $13.49, representing a 107.86% increase from its 52-week low, showcasing strong investor confidence in Tesla.
- Earnings Forecast: Intel Corporation (INTC) is scheduled to report earnings on April 23, 2026, with a consensus EPS forecast of -$0.11, reflecting a 2% increase over the previous year, indicating cautious optimism about its future performance.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
Amazon Launches GLP-1 Weight Loss Program
- Increased Market Competition: Amazon's launch of the GLP-1 management program through One Medical integrates obesity treatment with routine care, likely pressuring shares of companies like Hims & Hers Health and Viking Therapeutics, which fell following the announcement.
- Transparent Pricing: The pricing for GLP-1 medications will start as low as $25 per month for insured patients, aiming to attract more customers by simplifying access to medications and enhancing market share.
- Convenient Drug Delivery: Amazon plans to expand same-day drug delivery to 4,500 cities by the end of 2026, leveraging its robust logistics network to improve customer experience and gain an edge in the competitive weight loss drug market.
- Diverse Treatment Options: Through Amazon Pharmacy, patients can access various GLP-1 medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, further driving the company's expansion into the healthcare sector.
See More
Amazon Launches Comprehensive GLP-1 Management Program
- Fast Delivery Network: Amazon's GLP-1 medications are available for rapid delivery across all 50 states, with same-day service currently offered in nearly 3,000 cities and towns, and plans to expand to around 4,500 cities by the end of 2026, significantly enhancing customer accessibility and market reach.
- Pricing Strategy: Amazon's GLP-1 drug insurance plans start at $25 per month, with cash-pay options beginning at $149 per month, a pricing strategy aimed at attracting more consumers, particularly in a market with increasing demand for weight management medications.
- HIMS Stock Volatility: Hims & Hers Health Inc.'s stock fell approximately 4% following Amazon's GLP-1 management program launch, ending a six-session winning streak, reflecting market concerns over Amazon's competitive edge, despite the stock being down about 13% year-to-date.
- Regulatory Dynamics Impact: The FDA's openness to allowing compounding pharmacies to produce certain peptides could positively impact HIMS, as analysts believe this potential rule change will support HIMS's growth in commercial weight-loss products, enhancing its competitive position in the market.
See More
Amazon's GLP-1 Program Limits Impact Hims
- Amazon's GLP-1 Program Limits: Citi highlighted that Amazon's $29 telehealth option is restricted to prescription renewals, not new prescriptions, which may reduce the competitive threat to Hims' subscription model, impacting its market position.
- Hims Stock Volatility: Hims & Hers Health, Inc. (HIMS) saw its shares drop over 4% to $29.76 in extended trading on Tuesday, although they rebounded by more than 1% after hours, indicating mixed market sentiment regarding its future prospects.
- Hims Expanding New Areas: Hims is diversifying into hormone health, with the FDA recently encouraging testosterone therapy exploration for men with low libido, potentially opening new market opportunities while also advancing FDA-approved GLP-1 therapies.
- Positive Market Sentiment: Despite competition from Amazon, Hims has been viewed as “extremely bullish” on Stocktwits, with message volumes surging 384% over the past week, reflecting investor confidence in its innovative capabilities.
See More
Hims & Hers Stock Declines Amid Amazon Competition
- Stock Fluctuation: Hims & Hers Health closed at $29.76, down 4.03%, primarily impacted by Amazon's launch of a competing GLP-1 weight-loss program, although it gained 39.33% over the past week.
- Surge in Trading Volume: Trading volume reached 56.7 million shares, about 50% above the three-month average of 37.8 million shares, indicating increased market interest in the stock.
- Intensified Market Competition: Amazon's same-day delivery service poses a threat to Hims & Hers' core business, especially following the resolution of a legal dispute with Novo Nordisk over weight-loss drugs, which has dampened market sentiment.
- Investor Watch: Investors will closely monitor the potential impact of Amazon's new offering on Hims & Hers' revenue and subscriber numbers, particularly as the company is set to announce its Q1 results on May 11.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 99.53 points to 26,689.87, indicating positive market sentiment that may attract more investor interest.
- Active Stocks: Local Bounti Corporation (LOCL) increased by $1.0305 in pre-market trading, with a volume of 35,128,203 shares, indicating a significant uptick in the company's market activity.
- ETF Performance: Direxion Daily TSLA Bull 2X ETF (TSLL) rose by $0.2 to $13.49, representing a 107.86% increase from its 52-week low, showcasing strong investor confidence in Tesla.
- Earnings Forecast: Intel Corporation (INTC) is scheduled to report earnings on April 23, 2026, with a consensus EPS forecast of -$0.11, reflecting a 2% increase over the previous year, indicating cautious optimism about its future performance.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
Amazon Launches GLP-1 Weight Loss Program
- Increased Market Competition: Amazon's launch of the GLP-1 management program through One Medical integrates obesity treatment with routine care, likely pressuring shares of companies like Hims & Hers Health and Viking Therapeutics, which fell following the announcement.
- Transparent Pricing: The pricing for GLP-1 medications will start as low as $25 per month for insured patients, aiming to attract more customers by simplifying access to medications and enhancing market share.
- Convenient Drug Delivery: Amazon plans to expand same-day drug delivery to 4,500 cities by the end of 2026, leveraging its robust logistics network to improve customer experience and gain an edge in the competitive weight loss drug market.
- Diverse Treatment Options: Through Amazon Pharmacy, patients can access various GLP-1 medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, further driving the company's expansion into the healthcare sector.
See More
Amazon Launches Comprehensive GLP-1 Management Program
- Fast Delivery Network: Amazon's GLP-1 medications are available for rapid delivery across all 50 states, with same-day service currently offered in nearly 3,000 cities and towns, and plans to expand to around 4,500 cities by the end of 2026, significantly enhancing customer accessibility and market reach.
- Pricing Strategy: Amazon's GLP-1 drug insurance plans start at $25 per month, with cash-pay options beginning at $149 per month, a pricing strategy aimed at attracting more consumers, particularly in a market with increasing demand for weight management medications.
- HIMS Stock Volatility: Hims & Hers Health Inc.'s stock fell approximately 4% following Amazon's GLP-1 management program launch, ending a six-session winning streak, reflecting market concerns over Amazon's competitive edge, despite the stock being down about 13% year-to-date.
- Regulatory Dynamics Impact: The FDA's openness to allowing compounding pharmacies to produce certain peptides could positively impact HIMS, as analysts believe this potential rule change will support HIMS's growth in commercial weight-loss products, enhancing its competitive position in the market.
See More
